| Trial ID: | L2460 |
| Source ID: | NCT00846391
|
| Associated Drug: |
Mk8245 5 Mg (Twice A Day) B.i.d.
|
| Title: |
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00846391/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK8245 5 mg (twice a day) b.i.d.|DRUG: MK8245 50 mg b.i.d.|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4, The 24-hour WMG is derived from multiple glucose values collected during both fasting and post-meal periods. A "weighted" rather than a "simple" mean is used to avoid overrepresentation of post-meal glucose values. Blood samples for glucose were to be collected immediately prior to (sample -10 minutes), and 0, 15, 30, 60, 90, 120, and 180 minutes after each meal, and overnight (at midnight, 3 AM, and 5 AM) and fasting at 7 AM. Patients were to be domiciled for approximately 26 hours at the site where standard meals were provided and physical activity monitored., Baseline and Week 4 |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-12
|
| Completion Date: |
2009-08
|
| Results First Posted: |
2010-09-21
|
| Last Update Posted: |
2016-02-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00846391
|
